Merck’s Enflonsia to gain competitive advantage in paediatric RSV prophylaxis market with lack of… EP News Bureau Jun 16, 2025 FDA-approved Enflonsia enters US paediatric RSV market as the only prophylactic not requiring weight-based dosing, posing new…
